DesmoMelt

In April 2007 the licence for PNE was removed from the Desmospray formulation. This was because the very rare side effect of hyponatraemia had a lower reported incidence in the tablet formulation. Since then many patients have been moved to the oral forms of desmopressin - DesmoMelt and Desmotabs. DesmoMelt, launched in 2006, was designed to build on the efficacy and favourable safety profile of Desmotabs which have been available in the UK since 1988.

Much data has since been gathered on Desmotabs to confirm efficacy and tolerability. However, DesmoMelt has only been available for a relatively short time and measuring the incidence of a very rare side effect like hyponatraemia requires a large population exposure. In order to encourage reporting of such side effects, a black triangle has been assigned to all promotional materials. The MHRA has acknowledged that designing a safety study to assess hyponatraemia would be difficult because of the low incidence of this event. Desmopressin has been available since 1972 and therefore is a medication with a wealth of experience and studies. DesmoMelt was introduced with children in mind and the addition of the black triangle to this new formulation should ensure professionals are reminded of their responsibility to report any side effects and further improve medicine safety.

For further information please contact:

Medical Information
Ferring Pharmaceuticals Ltd
The Courtyard
Waterside Drive
Langley
Berkshire
SL3 6EZ

Telephone: 01753 214800, Fax: 01753 214801
Email: Medical@ferring.com

---------------------------------------------------------------

If you wish to see the latest news on desmopressin and enuresis, please choose product related news to the left. Please note that some of the tradenames for the desmopressin products differ from country to country.

Ferring will have a presence at the following events: